Results 231 to 240 of about 180,771 (310)

Identification of miR-155 targets to elucidate the role of high miR-155 levels in B cell Hodgkin and non-Hodgkin lymphoma

open access: green, 2007
Johan H. Gibcus   +7 more
openalex   +1 more source

Supplementary Figure S6 from Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma [PDF]

open access: gold
Maryam Pourmaleki   +15 more
openalex   +1 more source

Erythema annulare centrifugum and Hodgkin lymphoma during pregnancy

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Valentine Horiot   +7 more
wiley   +1 more source

Primary Cutaneous B‐Cell Lymphomas: An Updated Portrait of Classification, Biology, and Clinical Management

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Primary cutaneous B‐cell lymphomas (CBCL) represent a clinically and biologically heterogeneous group of extranodal non‐Hodgkin lymphomas confined to the skin at the time of diagnosis. They account for approximately 25% of all primary cutaneous lymphomas and are subclassified into distinct entities according to the World Health Organization ...
A. Bernardelli   +5 more
wiley   +1 more source

Leukemia cutis with concomitant acrodermatitis chronica atrophicans and chronic B‐cell lymphocytic leukemia: complete clearance under doxycycline therapy

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Sven‐Niklas Burmann   +5 more
wiley   +1 more source

Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Acute myeloid leukemia (AML) in elderly patients presents a major therapeutic challenge, as many are deemed unfit for intensive chemotherapy due to age, comorbidities, or frailty. Venetoclax in combination with hypomethylating agents (HMA) has emerged as a standard‐of‐care for this population, yet outcomes remain heterogeneous and predictive ...
Ernesto Vigna   +11 more
wiley   +1 more source

Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced-stage Hodgkin lymphoma in older patients. [PDF]

open access: yesHemasphere
Bröckelmann PJ   +17 more
europepmc   +1 more source

Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18–59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real‐Life Series From Southern Italy Cancer Centers

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT BV + AVD is increasingly used for frontline treatment of stage III/IV cHL. Young adults and adults (Ya&A) were the most common patients treated with BV + AVD in clinical trials but have not been studied in non‐trial settings. We conducted a real‐life study in secondary and tertiary cancer centers to evaluate the PFS in 18–59 years aged ...
Marco Picardi   +28 more
wiley   +1 more source

Home - About - Disclaimer - Privacy